Diabetes, Vol 49, Issue 6 926-935, Copyright © 2000 by American Diabetes Association

ARTICLES

Effects of glucosamine infusion on insulin secretion and insulin action in humans

T Monauni, MG Zenti, A Cretti, MC Daniels, G Targher, B Caruso, M Caputo, D McClain, S Del Prato, A Giaccari, M Muggeo, E Bonora and RC Bonadonna
Division of Endocrinology and Metabolic Diseases, University of Verona School of Medicine, Italy.

Glucose toxicity (i.e., glucose-induced reduction in insulin secretion and action) may be mediated by an increased flux through the hexosamine-phosphate pathway. Glucosamine (GlcN) is widely used to accelerate the hexosamine pathway flux, independently of glucose. We tested the hypothesis that GlcN can affect insulin secretion and/or action in humans. In 10 healthy subjects, we sequentially performed an intravenous glucose (plus [2-3H]glucose) tolerance test (IVGTT) and a euglycemic insulin clamp during either a saline infusion or a low (1.6 micromol x min(-1) x kg(-1)) or high (5 micromol x min(-1) x kg(-1) [n = 5]) GlcN infusion. Beta-cell secretion, insulin (SI*-IVGTT), and glucose (SG*) action on glucose utilization during the IVGTT were measured according to minimal models of insulin secretion and action. Infusion of GlcN did not affect readily releasable insulin levels, glucose-stimulated insulin secretion (GSIS), or the time constant of secretion, but it increased both the glucose threshold of GSIS (delta approximately 0.5-0.8 mmol/l, P < 0.03-0.01) and plasma fasting glucose levels (delta approximately 0.3-0.5 mmol/l, P < 0.05-0.02). GlcN did not change glucose utilization or intracellular metabolism (glucose oxidation and glucose storage were measured by indirect calorimetry) during the clamp. However, high levels of GlcN caused a decrease in SI*-IVGTT (delta approximately 30%, P < 0.02) and in SG* (delta approximately 40%, P < 0.05). Thus, in humans, acute GlcN infusion recapitulates some metabolic features of human diabetes. It remains to be determined whether acceleration of the hexosamine pathway can cause insulin resistance at euglycemia in humans.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. G. Albert, R. Fishman Oiknine, S. Parseghian, A. D. Mooradian, M. J. Haas, and T. McPherson The Effect of Glucosamine on Serum HDL Cholesterol and Apolipoprotein AI Levels in People With Diabetes Diabetes Care, November 1, 2007; 30(11): 2800 - 2803. [Abstract] [Full Text] [PDF]

				R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]

				B A Biggee, C M Blinn, M Nuite, J E Silbert, and T E McAlindon Effects of oral glucosamine sulphate on serum glucose and insulin during an oral glucose tolerance test of subjects with osteoarthritis Ann Rheum Dis, February 1, 2007; 66(2): 260 - 262. [Abstract] [Full Text] [PDF]

				R. Muniyappa, R. J. Karne, G. Hall, S. K. Crandon, J. A. Bronstein, M. R. Ver, G. L. Hortin, and M. J. Quon Oral Glucosamine for 6 Weeks at Standard Doses Does Not Cause or Worsen Insulin Resistance or Endothelial Dysfunction in Lean or Obese Subjects Diabetes, November 1, 2006; 55(11): 3142 - 3150. [Abstract] [Full Text] [PDF]

				J. L Stumpf and S.-W. Lin Effect of Glucosamine on Glucose Control Ann. Pharmacother., April 1, 2006; 40(4): 694 - 698. [Abstract] [Full Text] [PDF]

				M. G. Buse Hexosamines, insulin resistance, and the complications of diabetes: current status Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E1 - E8. [Abstract] [Full Text] [PDF]

				R. P. Robertson Chronic Oxidative Stress as a Central Mechanism for Glucose Toxicity in Pancreatic Islet Beta Cells in Diabetes J. Biol. Chem., October 8, 2004; 279(41): 42351 - 42354. [Full Text] [PDF]

				M.-J. J. Pouwels, C. J. Tack, P. N. Span, A. J. Olthaar, C. G. J. Sweep, F. C. Huvers, J. A. Lutterman, and A. R. M. M. Hermus Role of Hexosamines in Insulin Resistance and Nutrient Sensing in Human Adipose and Muscle Tissue J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5132 - 5137. [Abstract] [Full Text] [PDF]

				C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes Endocr. Rev., October 1, 2004; 25(5): 807 - 830. [Abstract] [Full Text] [PDF]

				M. Anello, D. Spampinato, S. Piro, F. Purrello, and A. M. Rabuazzo Glucosamine-induced alterations of mitochondrial function in pancreatic {beta}-cells: possible role of protein glycosylation Am J Physiol Endocrinol Metab, October 1, 2004; 287(4): E602 - E608. [Abstract] [Full Text] [PDF]

				D. A. Scroggie, A. Albright, and M. D. Harris The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-blinded, Randomized Clinical Trial Arch Intern Med, July 14, 2003; 163(13): 1587 - 1590. [Abstract] [Full Text] [PDF]

				J. G. Yu, S. M. Boies, and J. M. Olefsky The Effect of Oral Glucosamine Sulfate on Insulin Sensitivity in Human Subjects Diabetes Care, June 1, 2003; 26(6): 1941 - 1942. [Full Text] [PDF]

				R. C. Bonadonna, M. Stumvoll, A. Fritsche, M. Muggeo, H. Haring, E. Bonora, and T. W. van Haeften Altered Homeostatic Adaptation of First- and Second-Phase {beta}-Cell Secretion in the Offspring of Patients With Type 2 Diabetes: Studies With a Minimal Model to Assess {beta}-Cell Function Diabetes, February 1, 2003; 52(2): 470 - 480. [Abstract] [Full Text] [PDF]

				M.-J. J. Pouwels, P. N. Span, C. J. Tack, A. J. Olthaar, C. G. J. Sweep, B. G. van Engelen, J. G. de Jong, J. A. Lutterman, and A. R. Hermus Muscle Uridine Diphosphate-Hexosamines Do Not Decrease Despite Correction of Hyperglycemia-Induced Insulin Resistance in Type 2 Diabetes J. Clin. Endocrinol. Metab., November 1, 2002; 87(11): 5179 - 5184. [Abstract] [Full Text] [PDF]

				L. Ma, W. A. Rudert, J. Harnaha, M. Wright, J. Machen, R. Lakomy, S. Qian, L. Lu, P. D. Robbins, M. Trucco, et al. Immunosuppressive Effects of Glucosamine J. Biol. Chem., October 11, 2002; 277(42): 39343 - 39349. [Abstract] [Full Text] [PDF]

				L. Shane-McWhorter and P. Geil Interactions Between Complementary Therapies or Nutrition Supplements and Conventional Medications Diabetes Spectr, October 1, 2002; 15(4): 262 - 266. [Abstract] [Full Text] [PDF]

				M. Federici, R. Menghini, A. Mauriello, M. L. Hribal, F. Ferrelli, D. Lauro, P. Sbraccia, L. G. Spagnoli, G. Sesti, and R. Lauro Insulin-Dependent Activation of Endothelial Nitric Oxide Synthase Is Impaired by O-Linked Glycosylation Modification of Signaling Proteins in Human Coronary Endothelial Cells Circulation, July 23, 2002; 106(4): 466 - 472. [Abstract] [Full Text] [PDF]

				N. N. Chan, R. Osaki, C. C. Chow, J. C. N. Chan, C. S. Cockram, S. Molazowski, M. Feinglos, and B. Luna Drug-Related Hyperglycemia JAMA, February 13, 2002; 287(6): 714 - 715. [Full Text] [PDF]

				G. Arcaro, A. Cretti, S. Balzano, A. Lechi, M. Muggeo, E. Bonora, and R. C. Bonadonna Insulin Causes Endothelial Dysfunction in Humans: Sites and Mechanisms Circulation, February 5, 2002; 105(5): 576 - 582. [Abstract] [Full Text] [PDF]

				M.-J. J. Pouwels, J. R. Jacobs, P. N. Span, J. A. Lutterman, P. Smits, and C. J. Tack Short-Term Glucosamine Infusion Does Not Affect Insulin Sensitivity in Humans J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2099 - 2103. [Abstract] [Full Text]